Specialty Pharmacy

Smoking and obesity account for a significant number of cancers worldwide.

Commonwealth Fund researchers present ideas for increasing competition, applying value-based purchasing, and protecting patients from high out-of-pocket costs.

Researchers find that disputed bills amount to $54 billion annually across all health insurers.

Top news of the day from across the health care landscape.

Nivolumab plus ipilimumab demonstrated clinical benefit in previously treated patients with dMMR or MSI-H metastatic colorectal cancer.

Triple-negative and HER2-positive breast cancers may be unlikely to develop lymph node metastases.

The future affordability of health insurance coverage remains a concern for many Americans.

Innovative specialty drugs could result in more payers adopting value-based contracting.

Emergency departments are a safety net for low-income patients, many of whom may be at risk of HIV.

Researchers collaborate to test acoustic cluster therapy to improve treatment of pancreatic cancer.

Hospital Readmissions Reduction Program established through the Affordable Care Act found to penalize facilities that serve a large number of minority patients.

Mylan hopes to launch its newest HIV drug combo at a discounted cost.

Top news of the day from across the health care landscape.

CAR T-cell therapies and biosimilars require new strategies compared with traditional drugs.

Overweight patients with BRCA mutations may be more likely to develop breast cancer.

Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, discusses how specialty pharmacies can implement value-based reimbursement.

Besides tracking the Healthy Days metric, Humana has focused interventions around social determinants of health: food insecurity, loneliness, and social isolation.

Pharmacists play a vital role in the continuum of patient care.

The future of direct and indirect remuneration fees is in question, according to industry experts.

Top news of the week from Specialty Pharmacy Times.

Leukine’s approval adds to the United States’ available treatments for radiation exposure associated with treatment for cancer.

Immunotherapies for melanoma may be rendered ineffective by drug-resistant cells.

Top news of the day from across the health care landscape.

Officials with the FDA have expanded the approval of Amgen's blinatumomab (Blincyto) to include the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.

Health care providers should be aware of how HIV symptoms may affect menopausal women.

Lower respiratory infections remained the most lethal infectious disease in the United States.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Childhood obesity may have lasting effects that could permanently alter the likelihood of developing cancer.